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Abstract
Background: Clinical relevance of tumor infiltrating lymphocytes (TILs) in breast cancer is controversial. Here, we
used a tumor microarray including a large series of ductal and lobular breast cancers with long term follow up
data, to analyze clinical impact of TIL expressing specific phenotypes and distribution of TILs within different tumor
compartments and in different histological subtypes.
Methods: A tissue microarray (TMA) including 894 ductal and 164 lobular breast cancers was stained with
antibodies recognizing CD4, FOXP3, and IL-17 by standard immunohistochemical techniques. Lymphocyte counts
were correlated with clinico-pathological parameters and survival.
Results: CD4+ lymphocytes were more prevalent than FOXP3+ TILs whereas IL-17+ TILs were rare. Increased
numbers of total CD4+ and FOXP3+ TIL were observed in ductal, as compared with lobular carcinomas. High grade
(G3) and estrogen receptor (ER) negative ductal carcinomas displayed significantly (p < 0.001) higher CD4+ and
FOXP3+ lymphocyte infiltration while her2/neu over-expression in ductal carcinomas was significantly (p < 0.001)
associated with higher FOXP3+ TIL counts. In contrast, lymphocyte infiltration was not linked to any clinico-
pathological parameters in lobular cancers. In univariate but not in multivariate analysis CD4+ infiltration was
associated with significantly shorter survival in patients bearing ductal, but not lobular cancers. However, a FOXP3
+/CD4+ ratio > 1 was associated with improved overall survival even in multivariate analysis (p = 0.033).
Conclusions: Ductal and lobular breast cancers appear to be infiltrated by different lymphocyte subpopulations. In
ductal cancers increased CD4+ and FOXP3+ TIL numbers are associated with more aggressive tumor features. In
survival analysis, absolute numbers of TILs do not represent major prognostic indicators in ductal and lobular
breast cancer. Remarkably however, a ratio > 1 of total FOXP3+/CD4+ TILs in ductal carcinoma appears to represent
an independent favorable prognostic factor.
Background
Tumor-infiltrating lymphocytes (TILs) are frequently
considered to reflect host immune response against
malignant tumors [1]. TILs have been shown to infil-
trate a variety of tumors of diverse histological origin
[2,3]. Their exquisite tumor specificity has been demon-
strated in a number of cases and it has led to the char-
acterization of tumor associated antigens. Although
resident TILs have frequently been reported to be in a
functionally “anergic” state [4,5], importantly, following
“ex vivo“ culture, TILs have been used to treat different
types of cancers [6]. In line with these data, tumor infil-
tration by T lymphocytes has been shown to be asso-
ciated with favorable prognosis, particularly in
melanoma and colorectal cancers [2,7]. On the other
hand, tumor infiltration by T-lymphocytes subsets
endowed with immuno-regulatory or suppressive poten-
tial, e.g. CD4+ T-cells expressing FOXP3 transcription
factor, has been suggested to be associated with tumor
progression and unfavorable prognosis [8]. More
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recently, a CD4+ T-cell subset producing IL-17 has been
implicated in the pathogenesis of several autoimmune
diseases [9]. However, the role of the so-called Th17 in
antitumor immunity is still debated [10-13]
In normal breast tissue small numbers of lymphocytes
representing the mucosa-associated lymphoid tissue can
be detected [14]. In contrast, increased numbers of lym-
phocytes are frequently detectable around and within
breast cancers [15-18]. The clinical significance of TILs
in breast cancer is still controversial. In some studies,
TILs were associated with unfavorable characteristics
such as high grade tumors, estrogen receptor negativity,
basal-like molecular subtype as well as her2/neu positive
tumors [19,20]. High CD4+ and CD8+ lymphocytic infil-
tration has been associated with positive lymph node
status as well as worse overall survival [21]. Further-
more, in early stage breast cancer, CD8+ lymphocytic
infiltration has been suggested to correlate with lymph
node involvement [22]. Other groups, however, have
shown that breast cancers with increased TIL number
display a better prognosis in comparison with breast
cancers with lesser lymphocyte infiltration [23], as also
confirmed by data from our institution for CD8+ TILs
in the ER negative subgroup [24]. Additionally, high TIL
counts may represent an independent predictor of
response to neo-adjuvant chemotherapy [25]. Notably,
infiltration by FOXP3+ lymphocytes in breast cancer has
been proposed to represent an independent unfavorable
prognostic factor, especially in the nodal positive sub-
group [26] and to correlate with tumor invasiveness
[27]. In contrast, a complete clinical response has been
suggested to be associated with disappearance of tumor
infiltrating FOXP3+ T-cells during treatment [28].
While the clinical significance of TILs is controversial,
their distribution within stromal and intratumoral com-
partments in breast cancers is largely unknown. Further-
more, T-cell infiltration in different histological subtypes
as well as the occurrence of IL-17+ lymphocytes in
breast cancer tissue has not been reported to date. Here,
we addressed these issues by using a tissue microarray
(TMA) including a large number (> 1000) of breast can-
cers stratified according to ductal and lobular histologi-
cal subtypes. By taking advantage of a comprehensive
clinical follow-up database, numbers of CD4+, FOXP3+
and IL-17+ TILs and their occurrence in different tumor
compartments was correlated with clinico-pathological
features and survival data.
Methods
Breast cancer tissue microarray
The TMA utilized in this study includes 894 (84.5%) inva-
sive ductal and 164 (15.5%) lobular paraffin-embedded
breast cancers diagnosed at the Institute for Pathology,
University Hospital of Basel and at the Viollier Institute in
Basel between 1985 and 2007. For 386 (36%) tumors,
punches from center and periphery of cancerous tissues
were available. The median age of patients was 63 years
(range 28-94). The mean follow-up time was 84.5 months
(median: 75 months; range 1-263 months). Raw patient
survival data were obtained from the Cancer Registry of
Basel or from the patients’ attending physicians. TNM
classification and tumor diameter were obtained from
pathology reports. Hormone receptor and her2/neu status
data were available from a previous study from our group
[29]. TMA were dressed with materials from the Tissue
Biobank of the Institute of Pathology, University Hospital
Basel. This institution performs translational research with
approval of the EKBB (ethical committee Beider Basel) in
compliance with and specific regard to ethical standards
and patient confidentiality. The clinico-pathological char-
acteristics of the patients are listed in Table 1. Micro-inva-
sive carcinomas and carcinomas of T4 stage were
excluded from this study since microinvasion can hardly
be punched on a TMA and T4 breast cancers represent a
heterogeneous subgroup with ambiguous classification cri-
teria and different prognosis [30].
The TMA was constructed as previously described
[31]. Briefly, formalin-fixed, paraffin-embedded tissue
blocks of breast cancer samples were obtained. Tissue
cylinders with a diameter of 0.6 mm were punched from
morphologically representative cancer areas of a donor
tissue block and brought into a recipient paraffin block
(30 × 25 mm), using a semiautomated tissue arrayer.
Immunohistochemistry (IHC) and evaluation
Four-micron sections of the TMA blocks were incu-
bated with the following primary antibodies at the indi-
cated dilutions: mouse anti-human CD4 antibody (clone
1F6, Novocastra Labs, Newcastle. UK), undiluted (RU).
Monoclonal mouse anti-human FOXP3 (clone 236A/E7,
Abcam, Cambridge, UK), dilution: 1:20; purified polyclo-
nal goat anti-human IL-17 antibody (R&D Systems,
Minneapolis, Minnesota, USA), dilution 1:50; purified
polyclonal anti-human CD3 (Dako, Glostrup, Denmark),
dilution 1:600; monoclonal anti-human CD163; (clone
10D6, NeoMarkers, Fremont, CA), dilution 1:40.
Numbers of stained TILs were counted in each tissue
spot, representing approximately one 40x high-power-
field. Lymphocytes in contact or within the tumor
epithelium were scored as “intratumoral” whereas lym-
phocytes in the interstitial space were defined as “stro-
mal” (Figures 1 and 2).
Statistical analysis section
Differences in histo-pathological features between ductal
and lobular breast cancers were analyzed using Chi-
Square or Fisher’s Exact tests, while differences in the
number of TILs were investigated by using the non-
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parametric Wilcoxon Rank Sum test. Univariate survival
analysis was carried out with the log-rank test and prog-
nostic differences were illustrated using Kaplan-Meier
curves. Cut-off scores for high and low TILs were deter-
mined using receiver operating characteristic (ROC)
curve analysis. Additionally, multiple Cox regression
analysis was performed to test the independent prognos-
tic effect of TILs on outcome after adjusting for well-
established prognostic factors. The assumption of pro-
portional hazards was tested and validated by evaluating
the log(-log(survival)) versus log of survival time graphs.
Finally, correlations between different cell populations
were evaluated using Spearman’s rank correlation coeffi-
cient. In order to resolve the issue of multiple hypoth-
esis testing, a Bonferroni correction for multiple
comparisons was undertaken; hence p-values < 0.001
were considered statistically significant while values <
0.05 were identified as trends. Although the Bonferroni
correction is considered highly conservative, it was used
here to ensure a high level of confidence with regard to
the rejection of the null hypothesis. Analyses were per-
formed using SAS (V9.1, the SAS Institute, Cary, NC).
Results
Lymphocyte infiltration in breast cancer subtypes
Initially, we addressed overall lymphocyte infiltration in
breast cancer subtypes. Ductal breast cancers displayed
a higher CD4+ lymphocyte total (18.2 ± 25.3 vs. 11.1 ±
19.4; p = 0.014) and intratumoral infiltration as com-
pared to lobular tumors (12.6 ± 20.3 vs. 6.8 ± 14.1, p =
Table 1 Clinico-pathological characteristics of patient cohort
Feature Frequency n (%)
Ductal carcinoma (n = 894) Lobular carcinoma (n = 164)
pT stage pT1 369 (41.3) 52 (31.7)
pT2 475 (53.1) 90 (54.9)
pT3 50 (5.6) 22 (13.4)
pN stage pN0 485 (54.3) 90 (54.9)
pN1 340 (38.0) 67 (40.8)
pN2 69 (7.7) 7 (4.3)
Clinical stage IA 254 (28.4) 39 (23.8)
IIA 325 (36.4) 54 (32.9)
IIB 211 (23.6) 42 (25.6)
IIIA 104 (11.6) 29 (17.7)
BRE grade G1 181 (20.4) 24 (14.7)
G2 372 (41.9) 118 (72.4)
G3 334 (37.7) 21 (12.9)
ER status Negative 200 (23.7) 22 (14.4)
Positive 645 (76.3) 131 (85.6)
PR status Negative 346 (52.6) 65 (54.6)
Positive 312 (47.4) 54 (45.4)
Her-2/neu 0 and 1+ 680 (83.1) 130 (94.2)
2+ and 3+ 138 (16.9) 8 (5.8)
Molecular Subtypes Luminal A 160 (40.1) 30 (48.4)
Luminal B 7 (1.8) 0 (0.0)
Her2/neu 64 (16.0) 3 (4.8)
Triple Negative 168 (42.1) 29 (46.8)
Disease-specific survival death from breast cancer 72 (8.7) 9 (5.8)
Censored 760 (91.3) 145 (94.2)
5-year (95%CI) 94.0 (92-96) 97.0 (92-99)
Overall survival Death 172 (19.4) 34 (21.3)
Censored 714 (80.6) 126 (78.7)
5-year (95%CI) 85.6 (83-88) 87.8 (81-92)
Age at diagnosis (y) median 62 64
Minimum-maximum 28-94 38-90
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0.008). Infiltrating FOXP3+ cells were detectable to a
significantly higher extent within the tumor (4.0 ± 9.1
vs. 3.7 ± 14.4, p = 0.001) and in the stroma (4.2 ± 1.4
vs. 2.8 ± 6.1, p = 0.007) of ductal cancers as compared
to lobular breast cancers (Figure 3).
Remarkably, there was a significant correlation
between total CD4+ and FOXP3+ cells (p < 0.001; r =
0.47). This correlation was maintained in both ductal
and lobular carcinomas.
Only very few IL-17+ lymphocytes were detected in
either cancer subtype (ductal: 1.4 ± 3.0; lobular: 2.4 ±
5.4, p = 0.046), with a slight trend towards relatively
higher counts in the stromal compartment of lobular as
compared to ductal carcinomas (1.1 ± 2.3 vs. 1.8 ± 3.4;
p = 0.048).
Analysis of specimens (n = 386) for which two
punches from tumor center and periphery, respectively,
were available, did not show any significant difference in
infiltrate numbers for none of the markers under inves-
tigation: CD4 total (p = 0.951), CD4 intratumoral (p =
0.845), CD4 stromal (p = 0.297), FOXP3 total (p =
0.175), FOXP3 intratumoral (p = 0.11), FOXP3 stromal
(p = 0.916), IL17 total (p = 0.292), IL-17 intratumoral
and (p = 0.228) and IL17 stromal (p = 0.492).
High grade ductal carcinomas are associated with
increasing numbers of CD4+ and FOXP3+ lymphocytes
Next, the correlation between histological grading and
tumor infiltration was evaluated. In ductal carcinomas, a
significant (p < 0.001) association between higher total
Figure 1 Examples of CD4+, FOXP3+ and IL-17+ infiltrating lymphocytes in ductal and lobular breast cancer . A, B, C:
Immunohistochemical staining of breast cancer tissue punches incubated with anti-CD4 antibody (brown staining): A: Ductal breast cancer with
predominantly stromal and intratumoral CD4+ cells. B: Ductal breast cancer with prominent cell pleomorphism and easily detectable intratumoral
CD4+ cells, within the tumor and surrounding it. C: Example of an invasive lobular breast cancer with CD4+ cells. D; E: Zoom of breast cancers
incubated with anti-FOXP3 antibody (brown staining): D: Invasive ductal breast cancer with clear intratumoral infiltration by FOXP3+ cells. E:
Invasive lobular breast cancer with stromal and intratumoral FOXP3+ cells. F: Ductal breast cancer showing a single infiltrating IL-17+ cell (brown
staining). G/H: Ductal carcinoma with a FOXP3/CD4 ratio > 1. G shows the FOXP3 staining and H the CD4 staining. I/J: Lobular cancer with a
FOXP3/CD4 ratio < 1. I shows the FOXP3 staining and J the CD4 staining.
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and intratumoral numbers of CD4+ and FOXP3+ lym-
phocytes and histological grade [32] could be observed
(Table 2). In contrast, regarding lobular breast cancer
no association between lymphocyte infiltration and
tumor grade was detectable.
Lymphocyte infiltration and expression of estrogen and
progesterone receptors and her2/neu
The association of the prognostic and predictive mar-
kers estrogen and progesterone receptors (ER and PR),
and her2/neu expression with infiltration by different T-
cell subsets was then explored.
Significantly (p < 0.001) higher numbers of total and
intratumoral CD4+ and FOXP3+ TILs were detected
in ER negative as compared to positive ductal
carcinomas.
Loss of PR expression was associated with decreased
numbers of CD4+ T cells in ductal carcinomas (p =
0.008). However, no differences regarding FOXP3+ TILs
according to PR expression was seen. Her2/neu over-
expression was significantly (p < 0.001) associated with
increased numbers of tumor infiltrating FOXP3+ T cells
and by a similar trend for CD4+ lymphocytes (p =
0.023). These results are summarized in Table 3.
On the other hand, in lobular type of breast cancer no
association between hormone receptor status and distri-
bution of TIL was observed. All her2/neu over-expres-
sing lobular carcinomas regardless of their hormone
receptor status showed an increased infiltration by intra-
tumoral FOXP3+ cells (p = 0.002).
Notably, triple negative ductal carcinomas showed sig-
nificantly higher numbers of intratumoral (p < 0.001)
FOXP3+ TILs. The molecular subtype of her2/neu over-
expressing ductal breast cancers (ER-, PR-, her2/neu+)
showed an increased stromal (p = 0.003) and total (p =
0.002) number of FOXP3+ lymphocytes as compared to
the other molecular subtypes such as luminal A (ER+,
PR+, her2/neu-) or luminal B (ER+, PR+, her/neu2+). In
contrast, CD4+ T-cells infiltration did not appear to be
significantly associated with these molecular subgroups.
Once more, no significant association was detectable
in tumors of the lobular subtype. However, an associa-
tion of increased numbers of FOXP3+ intratumoral cells
could be found in the her2/neu over-expressing molecu-
lar subtype (ER-, PR-, her2/neu+) of lobular breast can-
cers (p = 0.006).
Lymphocyte infiltration and breast cancer staging
Higher total numbers of FOXP3+ (p = 0.026) lympho-
cytes were observed in small breast cancers (tumor size
≤ 2 cm; T1) with positive lymph nodes (N+), as com-
pared with tumors of the same T1 stage without lymph
node metastases (N0). However, in multivariate analysis,
infiltration by FOXP3+ cells did not represent an inde-
pendent factor when adjusted for stage. Notably, an
overall trend (p = 0.02) suggesting an association
between total number of FOXP3+ TIL and higher tumor
stage could be observed (Stage IA: 7.1 ± 13.6, Stage IIA:
7.9 ± 13.3, Stage IIB: 7.9 ± 13.7 and Stage: IIIA: 9.5 ±
15.8).
Lymphocyte infiltration and overall survival in patients
with breast cancer
Patients with ductal breast cancers infiltrated by high
total numbers of CD4+ lymphocytes showed a signifi-
cantly (p = 0.031) worse overall survival, as compared to
patients with lower CD4+ infiltration (Figure 4A).
Multivariate analysis, however, indicated that infiltra-
tion by CD4+ did not represent an independent prog-
nostic marker. In patients bearing lobular breast cancers
survival was not significantly associated with infiltration
by any lymphocyte subtype.
For 480 ductal and for 72 lobular carcinoma samples
FOXP3+/CD4+ cell ratios and overall survival data were
available. In ductal carcinoma, a FOXP3+/CD4+ > 1 was
significantly associated with better survival (p = 0.0005,
Figure 4B). This beneficial effect was maintained in a
multivariate analysis (n = 352) including pT, pN, BRE
Figure 2 Examples of CD3 and CD163 specific staining .
Immunohistochemistry of invasive ductal breast cancer infiltrated by
CD3+ (A, C) and CD163+ (B, D) cells (brown staining) in tumor
samples with FOXP3/CD4 ratios > 1 (A, B) and < 1 (C, D).
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grade, ER status and PR status (p = 0.033). In contrast,
in lobular carcinoma FOXP3+/CD4+ ratio was not sig-
nificantly associated with survival.
In order to obtain insights into the nature of FOXP3+
cells associated with favorable prognosis in ductal carci-
noma, TMA slides were stained with anti CD3 and anti
Figure 3 Box plot analysis of CD4+, FOXP3+ and IL-17+ cell distribution in ductal versus lobular carcinoma. Box plot analysis of
lymphocyte infiltration in ductal versus lobular carcinoma for CD4+, FOXP3+ and IL-17+ TILs. After adjustment for multiple comparisons, only p <
0.001 was considered statistically significant.
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CD163 Abs (Figure 2). We observed a higher tumor
infiltration by CD3 positive cells (average: 37.9 per
punch) than by CD163 positive cells (average: 21.6 per
punch). Most importantly, total FOXP3+ cell counts
were highly correlated with total numbers of CD3+ cells
(r = 0.503), and, in particular, with total CD8+ cell num-
bers (r = 0.507), but much less with total numbers of
CD163+ cells (r = 0.321).
Discussion
The adaptive immune system is known to play a major
role in the control of tumor progression in different
types of cancer. Indeed, tumor infiltration by CD8+ T-
cells has been shown to represent an important prog-
nostic factor in melanoma [7], and, more recently, in
colorectal cancers [2,33].
Early studies have suggested a favorable prognostic effect
of lymphocyte infiltration in breast cancers [34]. More
recently, infiltration by CD3+ T-cells has been suggested
to predict responsiveness to neoadjuvant treatment in
these tumors [25]. Furthermore, a predictive effect of
breast cancer infiltration by FOXP3+ cells has also been
reported [35]. Breast cancers, however, comprise histologi-
cally different tumor entities characterized by molecular
specificities and differential prognosis [36,37]. The expres-
sion of hormone receptors and her2/neu also represent
important factors in the biology of breast cancers and in
its prognosis [36]. Most importantly, phenotypes and loca-
tion of tumor infiltrating lymphocytes are emerging as
important issues in cancer immunobiology [7]. Therefore,
a thorough assessment of the immunobiological relevance
of lymphocyte infiltration in breast cancer needs to accu-
rately take into account these parameters.
Our data, deriving from the study of a large cohort of
cases, including > 1000 specimens, are consistent with a
significantly different pattern of lymphocyte infiltration
in ductal and lobular breast cancers. In the lobular his-
tological type, there is a lower lymphocytic infiltration
than in ductal cancers, particularly regarding CD4+ and
FOXP3+ cells. Furthermore, in lobular breast cancers,
lymphocyte infiltration is not correlated with tumor
grade and expression of hormonal receptors and it has
no prognostic relevance.
In contrast, in ductal cancers, increased infiltration by
CD4+ or FOXP3+ lymphocytes correlates significantly
with histological grade, and ER loss. Her2/neu over-
expression in ductal cancers is also significantly asso-
ciated with increased numbers of FOXP3+ infiltration.
Puzzlingly, loss of PR expression appears to be asso-
ciated with a decrease of CD4+ infiltrate. In agreement
with previous reports [27,38], we also found that FOXP3
+ infiltration is significantly increased in triple negative
ductal, but not in lobular breast cancers.
Whereas the molecular background underlying these
effects is unclear, they do impact the clinical course of
the disease, since in ductal cancers, high infiltration by
CD4+ T-cells is associated with a significantly more
severe prognosis, albeit only in univariate analysis.
On the other hand, in both ductal and lobular cancers
only a modest infiltration by IL-17 producing cells was
detectable.
Ductal breast cancers are more compactly growing
tumors, sometimes characterized by a broad and
Table 2 Correlation of CD4+ and FOXP3+ TILs and B.R.E.
grade of ductal carcinomas
Ductal carcinoma
Compartment/TIL
subtype
B.R.E. grade
1 2 3 p-
value*
Total
CD4+ 10.9 ±
21.2
18.0 ±
24.3
21.2 ±
26.2
< 0.001
FOXP3+ 4.8 ± 10.7 7.0 ± 11.4 11.2 ±
15.6
< 0.001
Intratumoral
CD4+ 7.5 ± 17.2 12.3 ±
20.1
14.8 ±
20.2
< 0.001
FOXP3+ 1.8 ± 5.8 3.1 ± 7.2 6.1 ± 11.8 < 0.001
Mean ± SD, counts of immunoreactive lymphocytes CD4+ and FOXP3+
Wilcoxon Rank Sum Test; *after adjustment for multiple comparisons, only p <
0.001 was considered statistically significant
Table 3 Correlation of CD4+ and FOXP3+ TILs with hormone receptor and her2/neu status in ductal carcinomas
Compartment/TIL subtype ER status PR status Her2/neu
- + p-value - + p-value - + p-value
Total
CD4+ 25.1 ± 29.7 15.6 ± 22.9 < 0.001 12.4 ± 19.3 17.9 ± 25.2 0.008 17.0 ± 24.5 22.4 ± 27.4 0.023
FOXP3+ 11.9 ± 16.1 6.9 ± 11.3 < 0.001 8.6 ± 13.4 6.7 ± 10.9 0.203 7.6 ± 12.6 10.6 ± 13.0 < 0.001
Intratumoral
CD4+ 17.5 ± 23.4 10.7 ± 18.5 < 0.001 8.2 ± 13.6 12.7 ± 21.6 0.032 11.7 ± 19.7 15.6 ± 21.8 0.036
FOXP3+ 7.0 ± 12.8 3.0 ± 7.0 < 0.001 4.0 ± 9.2 2.7 ± 6.1 0.12 3.7 ± 8.7 4.7 ± 8.1 0.009
Mean ± SD, counts of immunoreactive lymphocytes CD4+ and FOXP3+ Wilcoxon Rank Sum Test; *after adjustment for multiple comparisons, only p < 0.001 was
considered statistically significant
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pushing border, whereas lobular carcinomas mainly
show indian file pattern, smoothly infiltrating the sur-
rounding tissue. Interestingly, the detection of increasing
numbers of TILs in high grade tumors with pushing
borders was described earlier in medullary breast can-
cers [23]. In our study, higher counts of TILs are signifi-
cantly (p < 0.001) associated with more aggressive tumor
features such as loss of estrogen receptor, higher tumor
grade (G3), or her2/neu over-expression in ductal breast
cancers. More aggressive tumors are growing faster and
may therefore present more necrotic areas while produ-
cing stroma damage possibly related to local hypoxia
[39-42]. Indeed, increased numbers of CD4+ and FOXP3
+ cells under hypoxic condition could be shown in sev-
eral studies [43]. Therefore, the growth dynamics of the
tumor could play a role in inducing lymphocyte
infiltration.
FOXP3 represents a typical, although not exclusive,
marker of regulatory CD4+ T-cells. Tumor infiltration
by T-cells expressing this marker has been associated to
severe prognosis in different tumors, including ovarian
and lung cancers [8]. However, in colorectal cancers
FOXP3+ T-cell infiltration has been found to correlate
with significantly improved prognosis by us and others
[44,45]. Our data clearly document that, although num-
bers of FOXP3+ lymphocyte infiltration in ductal breast
cancer are significantly associated with unfavourable
clinico-pathological features, this marker alone does not
appear to represent a prognostic marker. However, a
high ratio (> 1) of total FOXP3+/CD4+ TILs was inde-
pendently associated with a better overall survival,
thereby suggesting that FOXP3+ cells other than CD4+
T lymphocytes could be involved in the elicitation of
the favorable prognostic effects. It is of note, that
although FOXP3 still represents one of the most reliable
Treg markers, it is known to be expressed by activated
T-cells as well [8]. Indeed, FOXP3 has been shown to
be expressed, albeit transiently, in activated CD8+ T
cells [46], in tonsillar suppressive CD8+ T cells [47], and
even in tumor cells [48].
Contrasting data have been reported regarding FOXP3
expression in tumor cells. In a mouse model FOXP3
could be identified as a X-linked tumor suppressor gene
in breast cancer [49], but others have failed to detect
expression of this gene in non hematopoietic tissues
[50]. FOXP3 expression has also been reported in
human breast cancer cells [26,51]. Other groups how-
ever, did not confirm these findings and only detected
FOXP3 expression in breast cancer infiltrating lympho-
cytes [35,52]. Furthermore evidence has been reported
that localization and activation status of FOXP3 positive
cells might play a prognostic role in breast cancer
[53,54]. Still unclear is the background underlying these
discrepancies, possibly related to the use of different
reagents and staining protocols. In our studies however,
in keeping with previous results [55] expression of
FOXP3 in breast cancer cells was found to be negligible
while it was usually detectable as nuclear staining of
TIL.
Accordingly, CD3 and CD163 specific staining data
indicate that tumor infiltration by FOXP3+ cells is highly
correlated with infiltration by CD3+ cells. Further stu-
dies are warranted to clarify nature, origin and functions
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Figure 4 Overall survival analysis in patients with ductal breast
cancer. A: Overall survival in patients with ductal carcinomas and
high and low level of CD4+ TILs. Kaplan-Meier survival curves
(univariate-analysis) of ductal breast cancers and overall survival in
patients with high level of CD4+ versus low level of CD4+ cells
infiltrating the tumor. CD4+ infiltrating cells: high level of CD4+
violet curve; low level of CD4+ black curve. Patients with high level
of CD4+ cell infiltration show a significant (p = 0.031) worse survival
(cut-off established by ROC curves: > 6 CD4+ TILs). B: Overall survival
in patients with ductal carcinomas according to total FOXP3/CD4
ratio > or < 1. Kaplan-Meier survival curves (univariate-analysis) of
ductal breast cancers and overall survival in patients with ratio of
total FOXP3+/CD4+ cells > 1 (blue curve) or < 1 (black curve).
Patients with a > 1 ratio had a significantly better survival (p =
0.0005).
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of FOXP3+ cells associated with improved survival in
ductal breast cancer. Nevertheless, our data suggest that
FOXP3 expression might reflect an activated state of
specific T cell subsets.
Our study indicates that ductal and lobular breast can-
cers are characterized by a significantly different pattern
of lymphocyte infiltration. Notably, in ductal cancers,
total and, in particular, intratumoral lymphocyte infiltra-
tion is significantly associated with higher histological
grade and severe prognosis, although not independently
from known prognostic factors.
Further research is warranted to clarify whether these
features are related to differential growth patterns of
these tumor types, or to a differential immunogenicity
of these tumors. Alternatively, variable tumor microen-
vironments might differentially favour lymphocyte che-
moattraction and expansion.
Conclusions
Our data, deriving from a large database, document that
breast cancers may be differentially infiltrated by lym-
phocytes depending on their histological subtype.
Furthermore, they indicate that tumor infiltration by
CD4+ or FOXP3+ cells is devoid of prognostic relevance.
Intriguingly however, they also suggest that breast can-
cer infiltration by CD4-/FOXP3+ lymphocytes might
represent an independent favorable prognostic factor.
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